Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Basal Cell 18Pancreatic Neoplasms 4Neoplasms 4Medulloblastoma 3Stomach Neoplasms 2Skin Neoplasms 2Ovarian Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Basal Cell Nevus Syndrome 2Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Solid Cancers 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pancreatic Diseases 1Osteosarcoma 1Odontogenic Cysts 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Neoplasms, Basal Cell 1Neoplasms by Site 1Neoplasms by Histologic Type 1Multiple Myeloma 1

Interventions

Paclitaxel 177Carboplatin 177Bevacizumab 72Topotecan 55liposomal doxorubicin 54Gemcitabine 53Cisplatin 46Docetaxel 39Cyclophosphamide 37olaparib 32Filgrastim 31pembrolizumab 29Doxorubicin 26niraparib 24Taxes 23Drug Therapy 23Peripheral Blood Stem Cell Transplantation 20Etoposide 17veliparib 15Nivolumab 14sargramostim 13Surveys and Questionnaires 13Immunoglobulin G 13Disulfides 13pazopanib 12Ifosfamide 12Albumin-Bound Paclitaxel 12durvalumab 11atezolizumab 11Trabectedin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Ovarian Neoplasms × HhAntag691 × Clear all
NCT00959647 2026-05-08

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Genentech, Inc.

Phase 2 Completed
19 enrolled 10 charts
DermatologicGastrointestinalGynecologic

Carcinoma, Basal Cell, Ovarian Neoplasms, Colorectal Neoplasms

NCT00739661 2017-06-08

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

Genentech, Inc.

Phase 2 Completed
104 enrolled 8 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡